FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366351641> ?p ?o ?g. }

• W4366351641 abstract "Abstract Background One of the key limitations of targeted cancer therapies is the rapid onset of therapy resistance. Taking BRAF-mutant melanoma as paradigm, we previously identified the lipogenic regulator SREBP-1 as a central mediator of resistance to MAPK-targeted therapy. Reasoning that lipogenesis-mediated alterations in membrane lipid poly-unsaturation lie at the basis of therapy resistance, we targeted fatty acid synthase (FASN) as key player in this pathway to evoke an exquisite vulnerability to clinical inducers of reactive oxygen species (ROS), thereby rationalizing a novel clinically actionable combination therapy to overcome therapy resistance. Methods Using gene expression analysis and mass spectrometry-based lipidomics of BRAF-mutant melanoma cell lines, melanoma PDX and clinical data sets, we explored the association of FASN expression with membrane lipid poly-unsaturation and therapy-resistance. Next, we treated therapy-resistant models with a preclinical FASN inhibitor TVB-3664 and a panel of ROS inducers and performed ROS analysis, lipid peroxidation tests and real-time cell proliferation assays. Finally, we explored the combination of MAPK inhibitors, TVB-3664 and arsenic trioxide (ATO, as a clinically used ROS-inducer) in Mel006 BRAF mutant PDX as a gold model of therapy resistance and assessed the effect on tumor growth, survival and systemic toxicity. Results We found that FASN expression is consistently increased upon the onset of therapy resistance in clinical melanoma samples, in cell lines and in Mel006 PDX and is associated with decreased lipid poly-unsaturation. Forcing lipid poly-unsaturation in therapy-resistant models by combining MAPK inhibition with FASN inhibition attenuated cell proliferation and rendered cells exquisitely sensitive to a host of ROS inducers. In particular, the triple combination of MAPK inhibition, FASN inhibition, and the clinical ROS-inducing compound ATO dramatically increased survival of Mel006 PDX models from 15 to 72% with no associated signs of toxicity. Conclusions We conclude that under MAPK inhibition the direct pharmacological inhibition of FASN evokes an exquisite vulnerability to inducers of ROS by increasing membrane lipid poly-unsaturation. The exploitation of this vulnerability by combining MAPK and/or FASN inhibitors with inducers of ROS greatly delays the onset of therapy resistance and increases survival. Our work identifies a clinically actionable combinatorial treatment for therapy-resistant cancer." @default.
• W4366351641 created "2023-04-21" @default.
• W4366351641 creator A5002960731 @default.
• W4366351641 creator A5003605224 @default.
• W4366351641 creator A5005521408 @default.
• W4366351641 creator A5005778227 @default.
• W4366351641 creator A5006152890 @default.
• W4366351641 creator A5010847260 @default.
• W4366351641 creator A5013468637 @default.
• W4366351641 creator A5016435003 @default.
• W4366351641 creator A5018013034 @default.
• W4366351641 creator A5022839444 @default.
• W4366351641 creator A5023527864 @default.
• W4366351641 creator A5024089610 @default.
• W4366351641 creator A5031459327 @default.
• W4366351641 creator A5032061607 @default.
• W4366351641 creator A5034389010 @default.
• W4366351641 creator A5040319024 @default.
• W4366351641 creator A5042687011 @default.
• W4366351641 creator A5047328481 @default.
• W4366351641 creator A5054734421 @default.
• W4366351641 creator A5054904657 @default.
• W4366351641 creator A5068737885 @default.
• W4366351641 creator A5076702762 @default.
• W4366351641 creator A5086938644 @default.
• W4366351641 creator A5091862786 @default.
• W4366351641 date "2023-04-19" @default.
• W4366351641 modified "2023-10-12" @default.
• W4366351641 title "Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy" @default.
• W4366351641 cites W1640815882 @default.
• W4366351641 cites W1834835434 @default.
• W4366351641 cites W1942089699 @default.
• W4366351641 cites W2000566591 @default.
• W4366351641 cites W2015012139 @default.
• W4366351641 cites W2025130458 @default.
• W4366351641 cites W2041993682 @default.
• W4366351641 cites W2047101066 @default.
• W4366351641 cites W2069116752 @default.
• W4366351641 cites W2080534618 @default.
• W4366351641 cites W2100614336 @default.
• W4366351641 cites W2108537717 @default.
• W4366351641 cites W2139126860 @default.
• W4366351641 cites W2144277227 @default.
• W4366351641 cites W2169934850 @default.
• W4366351641 cites W2317973866 @default.
• W4366351641 cites W2513656923 @default.
• W4366351641 cites W2549188196 @default.
• W4366351641 cites W2550324626 @default.
• W4366351641 cites W2554772583 @default.
• W4366351641 cites W2567412474 @default.
• W4366351641 cites W2612372140 @default.
• W4366351641 cites W2727828415 @default.
• W4366351641 cites W2739607402 @default.
• W4366351641 cites W2740630567 @default.
• W4366351641 cites W2761796839 @default.
• W4366351641 cites W2767055857 @default.
• W4366351641 cites W2808863372 @default.
• W4366351641 cites W2884607428 @default.
• W4366351641 cites W2896737734 @default.
• W4366351641 cites W2896804634 @default.
• W4366351641 cites W2905390578 @default.
• W4366351641 cites W2905917937 @default.
• W4366351641 cites W2913137771 @default.
• W4366351641 cites W2956607536 @default.
• W4366351641 cites W2957355938 @default.
• W4366351641 cites W2969491369 @default.
• W4366351641 cites W2980950801 @default.
• W4366351641 cites W2985539554 @default.
• W4366351641 cites W2994268592 @default.
• W4366351641 cites W2998864350 @default.
• W4366351641 cites W3044908880 @default.
• W4366351641 cites W3072295979 @default.
• W4366351641 cites W3086825172 @default.
• W4366351641 cites W3094620150 @default.
• W4366351641 cites W3109926818 @default.
• W4366351641 cites W3112871281 @default.
• W4366351641 cites W3126951521 @default.
• W4366351641 cites W3145730155 @default.
• W4366351641 cites W3168215909 @default.
• W4366351641 doi "https://doi.org/10.1186/s13046-023-02664-7" @default.
• W4366351641 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37072838" @default.
• W4366351641 hasPublicationYear "2023" @default.
• W4366351641 type Work @default.
• W4366351641 citedByCount "0" @default.
• W4366351641 crossrefType "journal-article" @default.
• W4366351641 hasAuthorship W4366351641A5002960731 @default.
• W4366351641 hasAuthorship W4366351641A5003605224 @default.
• W4366351641 hasAuthorship W4366351641A5005521408 @default.
• W4366351641 hasAuthorship W4366351641A5005778227 @default.
• W4366351641 hasAuthorship W4366351641A5006152890 @default.
• W4366351641 hasAuthorship W4366351641A5010847260 @default.
• W4366351641 hasAuthorship W4366351641A5013468637 @default.
• W4366351641 hasAuthorship W4366351641A5016435003 @default.
• W4366351641 hasAuthorship W4366351641A5018013034 @default.
• W4366351641 hasAuthorship W4366351641A5022839444 @default.
• W4366351641 hasAuthorship W4366351641A5023527864 @default.
• W4366351641 hasAuthorship W4366351641A5024089610 @default.
• W4366351641 hasAuthorship W4366351641A5031459327 @default.
• W4366351641 hasAuthorship W4366351641A5032061607 @default.
• W4366351641 hasAuthorship W4366351641A5034389010 @default.

• next